Blog Category

2020

Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure

,

/

23 June 2020

Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

,

/

11 June 2020

Biophytis announces the issue of 2,050,000 new shares in a capital increase reserved for NEGMA

,

/

10 June 2020

Results of the Combined General Meeting of May 28, 2020: All ordinary and extraordinary resolutions have been adopted

,

/

28 May 2020

Biophytis second AGM to take place on May 28, 2020 without the physical presence of its shareholders

,

/

20 May 2020

Biophytis Receives Approval from the Belgian Regulatory Agency (FAMHP) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure

,

/

20 May 2020

Biophytis shares resume trading following the implementation of measures ordered in connection with a dispute with NEGMA

,

/

19 May 2020

Convening of another combined General Meeting at a Later Date

,

/

11 May 2020

Biophytis shares and BSA trading is suspended pending a new press release

,

/

7 May 2020

Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders

,

/

30 April 2020

Biophytis Successfully Closes its Public Offering of Share Subscription Warrants (BSA)

,

/

27 April 2020

Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders

,

/

21 April 2020